256 related articles for article (PubMed ID: 33019903)
21. Cancer prevention and screening in women.
Melnikow J; Nuovo J
Prim Care; 1997 Mar; 24(1):15-26. PubMed ID: 9016727
[TBL] [Abstract][Full Text] [Related]
22. Reduced bladder cancer recurrence rate with cardioprotective aspirin after intravesical bacille Calmette-Guérin.
Gee JR; Jarrard DF; Bruskewitz RC; Moon TD; Hedican SP; Leverson GE; Nakada SY; Messing EM
BJU Int; 2009 Mar; 103(6):736-9. PubMed ID: 19007364
[TBL] [Abstract][Full Text] [Related]
23. Evaluation of PIK3CA mutation as a predictor of benefit from nonsteroidal anti-inflammatory drug therapy in colorectal cancer.
Domingo E; Church DN; Sieber O; Ramamoorthy R; Yanagisawa Y; Johnstone E; Davidson B; Kerr DJ; Tomlinson IP; Midgley R
J Clin Oncol; 2013 Dec; 31(34):4297-305. PubMed ID: 24062397
[TBL] [Abstract][Full Text] [Related]
24. The role of molecular tests for adjuvant and post-surgical treatment in gynaecological cancers.
Wijaya ST; Ngoi NY; Tan DS
Best Pract Res Clin Obstet Gynaecol; 2022 Jan; 78():14-35. PubMed ID: 34456153
[TBL] [Abstract][Full Text] [Related]
25. Nonsteroidal anti-inflammatory drugs and risk of ovarian cancer: systematic review and meta-analysis of observational studies.
Baandrup L; Faber MT; Christensen J; Jensen A; Andersen KK; Friis S; Kjaer SK
Acta Obstet Gynecol Scand; 2013 Mar; 92(3):245-55. PubMed ID: 23240575
[TBL] [Abstract][Full Text] [Related]
26. [Place of PARP inhibitors in the treatment of endometrial and cervical cancers].
Le Gac M; Koual M; Delanoy N; Perkins G; Nguyen-Xuan HT; Blons H; Le Frère-Belda MA; Laurent-Puig P; Bentivegna E; Durdux C; Azaïs H; Bats AS
Bull Cancer; 2022 Jan; 109(1):65-75. PubMed ID: 34801228
[TBL] [Abstract][Full Text] [Related]
27. mTOR inhibitors and their clinical application in cervical, endometrial and ovarian cancers: a critical review.
Husseinzadeh N; Husseinzadeh HD
Gynecol Oncol; 2014 May; 133(2):375-81. PubMed ID: 24556063
[TBL] [Abstract][Full Text] [Related]
28. Strategies for phase II cancer chemoprevention trials: cervix, endometrium, and ovary.
Kelloff GJ; Boone CW; Crowell JA; Nayfield SG; Hawk E; Steele VE; Lubet RA; Sigman CC
J Cell Biochem Suppl; 1995; 23():1-9. PubMed ID: 8747372
[TBL] [Abstract][Full Text] [Related]
29. Aspirin and Acetaminophen Use and the Risk of Cervical Cancer.
Friel G; Liu CS; Kolomeyevskaya NV; Hampras SS; Kruszka B; Schmitt K; Cannioto RA; Lele SB; Odunsi KO; Moysich KB
J Low Genit Tract Dis; 2015 Jul; 19(3):189-93. PubMed ID: 25856123
[TBL] [Abstract][Full Text] [Related]
30. Rational study endpoints in anti-neoplastic agent regulatory approval trials in the gynecologic malignancies.
Markman M
Womens Health (Lond); 2016 Jul; 12(4):396-9. PubMed ID: 27638892
[TBL] [Abstract][Full Text] [Related]
31. Aspirin and epithelial ovarian cancer.
Akhmedkhanov A; Toniolo P; Zeleniuch-Jacquotte A; Kato I; Koenig KL; Shore RE
Prev Med; 2001 Dec; 33(6):682-7. PubMed ID: 11716667
[TBL] [Abstract][Full Text] [Related]
32. Aspirin and cancer risk: an update to 2001.
Bosetti C; Gallus S; La Vecchia C
Eur J Cancer Prev; 2002 Dec; 11(6):535-42. PubMed ID: 12457105
[TBL] [Abstract][Full Text] [Related]
33. Association between intrauterine device use and endometrial, cervical, and ovarian cancer: an expert review.
Minalt N; Caldwell A; Yedlicka GM; Joseph S; Robertson SE; Landrum LM; Peipert JF
Am J Obstet Gynecol; 2023 Aug; 229(2):93-100. PubMed ID: 37001577
[TBL] [Abstract][Full Text] [Related]
34. Aspirin, other NSAIDs, and ovarian cancer risk (United States).
Fairfield KM; Hunter DJ; Fuchs CS; Colditz GA; Hankinson SE
Cancer Causes Control; 2002 Aug; 13(6):535-42. PubMed ID: 12195643
[TBL] [Abstract][Full Text] [Related]
35. Nonsteroidal anti-inflammatory drugs and risk for ovarian and endometrial cancers in the Iowa Women's Health Study.
Prizment AE; Folsom AR; Anderson KE
Cancer Epidemiol Biomarkers Prev; 2010 Feb; 19(2):435-42. PubMed ID: 20142241
[TBL] [Abstract][Full Text] [Related]
36. Effect of aspirin on long-term risk of colorectal cancer: consistent evidence from randomised and observational studies.
Flossmann E; Rothwell PM;
Lancet; 2007 May; 369(9573):1603-13. PubMed ID: 17499602
[TBL] [Abstract][Full Text] [Related]
37. Screening for cancer, 1995: an update.
La Vecchia C; Levi F; Franceschi S
Ann Oncol; 1995 Jul; 6(6):537-41. PubMed ID: 8573531
[No Abstract] [Full Text] [Related]
38. Physical activity and gynecologic cancer prevention.
Cust AE
Recent Results Cancer Res; 2011; 186():159-85. PubMed ID: 21113764
[TBL] [Abstract][Full Text] [Related]
39. Trends in gynaecological cancers in the largest obstetrics and gynaecology hospital in China from 2003 to 2013.
Li X; Zheng S; Chen S; Qin F; Lau S; Chen Q
Tumour Biol; 2015 Jul; 36(7):4961-6. PubMed ID: 25649977
[TBL] [Abstract][Full Text] [Related]
40. ACOG committee opinion. Routine cancer screening. Number 247, December 2000.
ACOG committee
Int J Gynaecol Obstet; 2003 Aug; 82(2):241-5. PubMed ID: 12926412
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
